UroGen Pharma Ltd.

NASDAQ:URGN

Biotechnology

Healthcare
$29.79 -1.22%

-$0.40 today

Market cap
$1.46B
Beta
1.62
P/E (TTM)
-12.2
EPS (TTM)
-$2.65
52W Low $12.73High $33.79

Volume 1.14M

Average 0.79M

URGN Pre-Tax Margin

Income before tax as a percentage of revenue.

UroGen Pharma Ltd.NASDAQ: URGN

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin widens to -55.6%

Pre-tax margin was -55.6% in Q1 FY2026, up 158.9 pp from a year earlier. On a trailing-twelve-month basis it was -98.4%, up 48.8 pp year over year. Over 3 fiscal years it widened by 28.1 pp.

Context

  • Pre-tax margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-55.6%+14.8 pp QoQ
Last fiscal yearDec 2025
-139.7%-2.5 pp YoY
LTMMar 2026
-98.4%+48.8 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+158.9 pp——
1 year-2.5 pp——
3 years+28.1 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-139.7%
Year-over-year change
-2.5pp

Pre-Tax Margin vs competitors

How URGN compares with its peers on the latest reported figures

  • URGN's LTM Mar 2026 pre-tax margin of -98.4% is the highest of the 2 companies compared; the peer median is -3851.1%.
  • Its year-over-year change of +48.8 pp is the lowest of 2, against a peer median of +3116.9 pp.
  • Over three fiscal years its change of +28.1 pp compares with a peer median of +14571.5 pp.
URGN Competitors Peer median
Pre-Tax Margin for URGN and competitors
Company Period LTM level YoY 3-year change
URGNUroGen Pharma Ltd.LTM Mar 2026-98.4% +48.8 pp+28.1 pp
CGONCG Oncology, Inc. Common stockLTM Sep 2026-3851.1% +3116.9 pp+14571.5 pp
RLMDRelmada Therapeutics, Inc.FY2025— ——
Peer median (excluding URGN) -3851.1%+3116.9 pp+14571.5 pp

Competitors are the stored peer set for URGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue48.04M64.36M82.71M90.4M109.79M
Cost of Revenue5.16M7.65M9.36M8.88M12.45M
Gross Profit42.89M56.7M73.35M81.52M97.34M
Gross Margin89.3%88.1%88.7%90.2%88.7%
Research & Development47.64M52.91M45.61M57.15M67.11M
Selling, General & Admin082.84M93.27M0155.1M
Operating Expenses135.18M135.74M138.89M178.3M222.2M
Depreciation & Amortization831K1.82M1.71M329K2.41M
EBITDA(108.54M)(76.21M)(60.35M)(95.35M)(135.66M)
EBITDA Margin-225.9%-118.4%-73.0%-105.5%-123.6%
Operating Income(92.29M)(79.04M)(65.54M)(96.78M)(124.86M)
Operating Margin-192.1%-122.8%-79.2%-107.1%-113.7%
Interest Income365K938K2.64M8.9M5.97M
Interest Expense17.44M8.44M14.72M12.52M33.85M
Other Income / Expenses(17.08M)(28.99M)(32.79M)(27.26M)(28.55M)
Income Before Tax(109.37M)(108.03M)(98.32M)(124.04M)(153.42M)
Pre-Tax Margin-227.7%-167.9%-118.9%-137.2%-139.7%
Income Tax Expense1.45M1.76M3.92M2.83M78K
Net Income(110.82M)(109.78M)(102.24M)(126.87M)(153.49M)
Net Margin-230.7%-170.6%-123.6%-140.4%-139.8%
EPS (Basic)(4.96)(4.79)(3.55)(2.96)(3.19)
EPS (Diluted)(4.96)(4.79)(3.55)(2.96)(3.19)
Weighted Avg Shares22.35M22.81M28.83M42.88M48.12M
Weighted Avg Shares (Diluted)22.35M22.81M28.83M42.88M48.12M

UroGen Pharma Ltd.

NASDAQ:URGN

Intrinsic Alpha fair value

Locked

Current Price

$29.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.